Tag: X

SINGAPORE, June 12, 2025 (GLOBE NEWSWIRE) -- HTX, a leading global cryptocurrency exchange, officially launched its highly anticipated TRX options products on June 11, further enhancing its robust derivatives offerings. This development provides users with greater trading flexibility and additional tools to manage risk and pursue profit in a dynamic market environment. The introduction of TRX options marks a key step in HTX's strategic roadmap toward a comprehensive and resilient derivatives ecosystem. Through ongoing product innovation, HTX continues to reinforce its competitive edge in the global derivatives market.

VICTORIA, Seychelles, June 12, 2025 (GLOBE NEWSWIRE) -- MEXC, a leading global cryptocurrency exchange, has unveiled a groundbreaking $100 million Guardian Fund to enhance user safety and trust across its platform. This fund is designed to provide a strong safeguard for users facing severe security threats, such as large-scale exploits, targeted attacks, or unforeseen system vulnerabilities. In a move toward greater accountability, MEXC has made the fund fully transparent by disclosing wallet addresses publicly—setting a new industry standard for proactive risk management and user protection.

Press release
Paris, 12 June 2025

Communiqué de presse
Paris, 12 juin 2025

BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology’s annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO.